YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

The Effect of Tetramethoxyflavone on the Pharmacokinetics of Paclitaxel in Rats

테트라메톡시프라본이 파크리탁셀의 약물동태에 미치는 영향

  • Published : 2004.08.01
Download PDF
⟨ Previous Next ⟩

Abstract

The pharmacokinetics of orally administered paclitlxel (50 mg/kg) was studied in six rabbits after 1hr pretreatment (2.0 mg/kg and 10 mg/kg) of tetramethoxyflavone or coadministration of (2.0 mg/kg, 10 mg/kg and 20 mg/kg) tetramethoxyflavone. The area under the plasma concentration-tine curve (AUC) and plasma concentration of paclitaxe1 coadministered with tetramethoxyflavone (10 mglkg) were increased significantly (p<0.05) compared with control. However, coadministration of tetramethoxyflavone (2 and 20 mg/kg) showed no significant effect on the pharmacokinetic parameters of paclitaxel. Pretreatment with tetramethoxyflavone significantly (p<0.05) increased the plasma concentration of paclitaxel. The area under the plasma concentration-time curve (AUC) and the peak concentration (C$_{max}$) of paclitaxel pretreated with tetramethoxyflavone were increased significantly (p<0.01, p<0.05) compared with control. The terminal half. life of paclitaxel pretreated with tetramethoxyflavone (2 mg/kg and 10 mg/kg) was significantly (p<0.05) prolonged compared with control. Pretreatment with tetramethoxyflavone (2.0 mg/kg, 10 mg/kg) significantly (p<0.01, p<0.05) increased the absolute bioavailability of paclitaxel compared with the control (154∼179%). On the basis of the results, it might be considered that tetramethoxyflavone may inhibit cytochrome P450 or P-glycoprotein efflux pump which are engaged in paclitaxel metabolism, result in increased AUC and t$_{1}$2/ of paclitaxel. However, further study should be conducted to clarify the roles of cytochrome P450 and P-glycoprotein on paclitaxel bioavailability with/or without tetramethoxyflavone. P-glycoprotein on paclitaxel bioavailability with/or without tetramethoxyflavone.

Keywords

References

  1. Donehower R. C., Rowinsky, E. K., Grochow, L. B. et al. : Phase I trial of taxol in patients with advanced malignancies. cancer Treat. Rep. 71, 1171 (1987)
  2. Legha, S. S., Tenney, D. M. and Krakhoff, I. R. : Phase I study of taxol using a 5-day intermittent schedule. J. Clin. Oncol. 5, 1232 (1987)
  3. Einzig, A. I., Hochster, H., Wiernik , P. H. et al. : A phase II study of taxol in patients with malignant melanoma. Invest. New. Drugs. 9, 59 (1991)
  4. McGuire, W. P., Rowinsky, E. K., Rosenheim, N. B. et al. : Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasm. Ann. Intern. Med. 111, 273 (1989)
  5. Einzig, A. I., Wiernik, P. H., Saslooff, J. et al. : Phase II study and long-term follow up of patients treated with taxol for advanced ovarian adenocarcinoma. J. Clin. Oncol. 10, 1748 (1992)
  6. Einzig, A. I., Gorowski, E., Sadloff, J. et al. : Phase II trial of taxol in patients with metastatic renal cell carcinoma. Cancer Invest. 9, 133 (1991) https://doi.org/10.3109/07357909109044223
  7. Sarosy, G., Kohn, E.,Stone, D. A. et al. : Phase I study of taxol and granulocyte stimulation factor in patients with refractory ovarian cancer. J. Clin. Oncol. 10, 1165 (1992)
  8. Wiernik, P. H., Schwartz, E. I., Einzig, A. et al. : Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses seen in metastatic melanoma. J. Clin. Omcol. 5, 1232 (1987)
  9. Grem, J. L., Tutsch, K. D., Simon, K. L. et al. : Phase I study of taxol administered as a short iv infusion daily for 5 days. Cancer Treat. Rep. 71, 1179 (1987)
  10. Rowinsky, E. K., Gilbert , M. R., McGuire, W. P. et al. : Sequences of taxol and cisplatin: A phase I and pharmacologic study. J. Clin. Oncol. 9, 1692 (1991)
  11. Watkins, P. B. : The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27, 161 (1997) https://doi.org/10.1016/S0169-409X(97)00041-0
  12. Wacher V. H., Silverman, J. A., Zhang, Y. and Benet, L. Z. : Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87, 1322 (1998) https://doi.org/10.1021/js980082d
  13. Rahman, A., Korzekwa, K. R., Grogan, J., Gonzalez, F. J. and Harris, J. W. : Selective biotransformation of taxol to 6 $\alpha$-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54, 5543 (1994).
  14. Sonnichsen, D. S., Liu, Q., Schuetz, E. G., Schuetz, J. D., Pappo, A. and Reiling, M. V. : Variability in human cytochrome P450 paclitaxel metabolism.J. Pharmacol. Exp. Ther. 275 , 566 (1995)
  15. Walle, T. : Short communication; Taxol metabolism in rat hepatocytes. Biochem. Pharmacol. 46, 1661 (1993) https://doi.org/10.1016/0006-2952(93)90336-U
  16. Sonnichsen, D. S. and Reiling, M. V. : Clinical Pharmacokinetics of paclitaxel. Clin. Pharmacokinet. 27, 256 (1994) https://doi.org/10.2165/00003088-199427040-00002
  17. Harris, J. W., Rahman, A., Kim, B. R., Guengerich, F. P. and Collins, J. M. : Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54, 4026 (1994)
  18. Ito, K., Kusuhara, H. and Sugiyama, Y. : Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption-theoretical approach. Pharm. Res. 16, 225 (1999) https://doi.org/10.1023/A:1018872207437
  19. Kutz, B. S., Wellzel, U. and Daniel, H. : Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. Eur.J. Nutr. 38, 133 (1999) https://doi.org/10.1007/s003940050054
  20. Koide, T., Kamei, H., Hashimoto, Y., Kojima, T., Terabe , K. and Umeda, T. : Influence of flavonoids on cell cycle phase as analyzed by flowcytometry. Cancer Biother Badiopharm. 12, 111 (1997) https://doi.org/10.1089/cbr.1997.12.111
  21. Conseil, G., Baubichon-cortary, H., Dayan, G., Jault, J. M., Barron, D. and dl Pietro , A. : Flavonoids : a class of modulators with bifunctional interactions at vicinal ATP-and steroid binding sites on mouse P-glycorortein. Proc. Natl. Acad. Sci. USA 95, 9831 (1998)
  22. Soambia, G., Ranelletti, F. O., Panici, P. B., Vincenzo, De R., Bonanno, G., Frrandina, G., Piantelli, M., Bussa, S., Rumi, C., Ciantriglia, M. et al. : Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breastcancer cell line : P-glycoprotein as a possible target. Cancer Chemother Pharmacol. 36, 448 (1995)
  23. Choi, C. H., Romiti, N., Cervelli, F. and Tongiani, R. : Effect of flavonols on P-glycoprotein activety in cultured rat hepatocytes. Life Sciences 57, 1741 (1995) https://doi.org/10.1016/0024-3205(95)02152-9
  24. Ikegawa, T., Ohtani, H., Koyabu, N., Juichi, M., Iwase, Y., Ito, C., Furukawa, H., Naito, M., Tsuruo, T. and Sawada, Y. : Inhibition of P-glycoprotein by flavonoid derivatives in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Lett. 177, 89 (2002) https://doi.org/10.1016/S0304-3835(01)00761-3
  25. Kumar, G. N., Walle, U. K. and Walle, T : Cytochrome P450 3A-mediated human liver microsomal taxol 6$\alpha$-hydroxylation. J. Pharmacol. Exp. Ther. 268(3), 1160 (1994)
  26. Doostdar, H., Burke, M. D. and Mayer, R. T. : Bioflavoniods : selective substrates and inhibitors for cytochrome P450 CYPIA and CYPIB1. Toxicology 144, 31 (2000) https://doi.org/10.1016/S0300-483X(99)00215-2
  27. Zhang, H., Wong, C. W., Coville, P. G. and Wanwimo.ruk, S.: Effect of the grapefruit flavonoid naringen on pharmacokinetics of quinine in rats. Drug Metabol. Drug Interact . 17,351 (2000)
  28. Souza, M. F, Tome, A. R. and Rao, V. S. : Inhibition by the bioflavonoid ternatin of aflatoxin B1-induced lipid peroxidation in rat liver. J. Pharm. Pharmacol. 51, 125 (1999) https://doi.org/10.1211/0022357991772222
  29. Rao, V. S., Figueiredo, E. G., Melo, C. L., Viana, G. S., Menezes, D. B., Matos, M. S. and Silveira, E. R. : Protective effect of ternatin, a flavonoid isolated from Egletes viscosa less. , in experimental liver injury. Pharmacology 48, 392 (1994)
  30. Nagao, T., Abe, F, Kinjo, J. and Okabe, H. : Antipreliferative constituents in plants 10. Flavones from the leaves of Lantana montevidensis Briq. and consideration of structure-activity relationship. Biol. Pharm. Bull. 25, 875 (2002)
  31. Yenjai, C., Prasanphen, K., Daodee, S., Wongpanich, V. and Kittakoop, P. : Bioactive flavonoids from Kaempferia parviflora. Fitoterapia . 75, 89 (2004) https://doi.org/10.1016/j.fitote.2003.08.017
  32. Choi, C. H., Sun, K. H., An, C. S., Yoo, J. C., Hahm, K. S., Lee, I.H., Sohng, J. K. and Kim, Y. C. : Reversal of P-glycoprotein mediated multidrug resistance by 5,6,7,3’,4’-pentamethoxy-flavone (Sinensetin). Biochem. Biophys. Res. Commun . 295, 832 (2002) https://doi.org/10.1016/S0006-291X(02)00755-6
  33. Marin, N., Catalin, J., Blachon, M. F. and Durand, A. : Assay of paclitaxel (Taxol) in plasma and urine by high performance liquid chromatogrphy. J. Chromato. B. 709 , 281-288 (1998)
  34. Mase, H., Hiraoka, M. and Suzuki, F : Determination of new anticancer drug, paclitaxel, in biological fluids by high performance liquid chromatography. Yakugaku. Zasshi. 114, 351 (1994)
  35. Rocci, M. L. and Jusko, W. J. : LAGRAN program for area and monents in pharmacokinetic analysis. Computer Program in Biomedicine. 16, 203 (1983) https://doi.org/10.1016/0010-468X(83)90082-X
  36. Choi, J. S., Jo, B. W. and Kim, Y. C. : Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur.J. Pharm. Biopharm. 57, 313 (2004) https://doi.org/10.1016/j.ejpb.2003.11.002
  37. Choi, J. S., Choi, H K. and Shin, S. C.: Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int. J. Pharm. 275, 165 (2004) https://doi.org/10.1016/j.ijpharm.2004.01.032